资讯
智通财经APP获悉,在诺和诺德(NVO.US)终止与远程医疗公司Hims & Hers Health合作后,摩根士丹利发布研报给予Hims & Hers ...
在诺和诺德 (NVO.US)终止与远程医疗公司Hims & Hers Health合作后,摩根士丹利发布研报给予 Hims & Hers Health (HIMS.US)“与大盘持平”评级,最新目标价40美元。
Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
智通财经APP获悉, 诺和诺德 (NVO.US)近日与WeightWatchers (WGHTQ.US)达成合作协议销售其减肥药Wegovy。此前,这家丹麦制药巨头刚终止了与远程医疗公司Hims & Hers Health ...
在今日的股市交易中,Hims & Hers Health公司股价大幅下跌28.4%,成为市场关注的焦点。该公司的股价反应强烈,主要是由于诺和诺德宣布停止与其合作,市场对此消息的敏感度显而易见,投资者纷纷调整持仓以应对潜在风险。
摩根士丹利 分析师在研报中指出,Hims & Hers Health面临的核心问题在于,若 诺和诺德 对其发起诉讼,该公司能否继续提供复合式GLP-1药物疗法。
1 天
Zacks Investment Research on MSNHims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...
Hims & Hers (NYSE: HIMS) is attracting investors looking to buy the dip in this impressive growth stock. Where to invest ...
7 天on MSN
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
Hims & Hers Health作为健康科技行业的代表之一,近期在市场上受到广泛关注。然而,合作关系的终止让投资者感到不安,尽管如此,市场的整体情绪依然复杂。诺和诺德的股价在盘前也下跌超过5%,这一连锁反应引发了市场的广泛讨论。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果